New drug combo tested for advanced breast cancer in chinese women
NCT ID NCT02499146
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested the drug palbociclib (combined with letrozole) in 26 postmenopausal Chinese women with a specific type of advanced breast cancer (ER+, HER2-). The main goal was to see how the drug moves through the body and to check for safety. The study is complete, and results help guide future use in this population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Palbociclib (a targeted cancer drug) and Letrozole (a hormone therapy)
What this could lead to
If successful, this study could help confirm that palbociclib works similarly in Chinese patients, supporting its use as a treatment for advanced breast cancer in this population.
What could go wrong
This is a very early (Phase 1) study with only 26 participants, focused on drug levels in the body, not on curing cancer. Side effects are possible, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital/Oncology department
Beijing, Beijing Municipality, 100142, China
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, 100021, China
-
Guangdong General Hospital/Department of Breast Surgery
Guangzhou, Guangdong, 510080, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
-
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of College of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
-
The first hospital of jilin university
Changchun, Jilin, 130021, China